My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 161

    1.

    The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

    Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, et al.

    Ann Intern Med. 1991 Jan 15;114(2):119-27.PMID: 1984386 [PubMed - indexed for MEDLINE]Related articles

    2.

    Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

    Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, et al.

    AIDS Res Hum Retroviruses. 1994 Dec;10(12):1713-23.PMID: 7888231 [PubMed - indexed for MEDLINE]Related articles

    3.

    Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.

    Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G.

    AIDS Res Hum Retroviruses. 1990 Nov;6(11):1251-6.PMID: 1706607 [PubMed - indexed for MEDLINE]Related articles

    4.

    Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

    Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE.

    Ann Intern Med. 1996 Aug 15;125(4):270-9.PMID: 8678389 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

    Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al.

    J Infect Dis. 1993 Mar;167(3):533-7.PMID: 8095059 [PubMed - indexed for MEDLINE]Related articles

    6.

    Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.

    Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB.

    Vaccine. 1994 Aug;12(10):912-8.PMID: 7975833 [PubMed - indexed for MEDLINE]Related articles

    7.

    Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.

    Gorse GJ, Frey SE, Newman FK, Belshe RB.

    J Clin Microbiol. 1992 Oct;30(10):2606-12.PMID: 1400960 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.

    Haubrich RH, Takeda A, Koff W, Smith G, Ennis FA.

    J Infect Dis. 1992 Mar;165(3):545-8.PMID: 1538159 [PubMed - indexed for MEDLINE]Related articles

    9.

    Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

    Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS, Bhat BM, Mizutani S, Lee S, et al.

    Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7777-81.PMID: 1502197 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

    Kovacs JA, Vasudevachari MB, Easter M, Davey RT, Falloon J, Polis MA, Metcalf JA, Salzman N, Baseler M, Smith GE, et al.

    J Clin Invest. 1993 Aug;92(2):919-28.PMID: 7688766 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.

    Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R.

    AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93.PMID: 8744579 [PubMed - indexed for MEDLINE]Related articles

    12.

    Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.

    Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC.

    J Infect Dis. 1991 Mar;163(3):448-53.PMID: 1995718 [PubMed - indexed for MEDLINE]Related articles

    13.

    Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

    Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, et al.

    J Infect Dis. 1993 Dec;168(6):1387-95.PMID: 8245523 [PubMed - indexed for MEDLINE]Related articles

    14.

    Salivary antibodies to human immunodeficiency virus type 1 in a phase I AIDS vaccine trial.

    Archibald DW, Hebert CA, Sun D, Tacket CO.

    J Acquir Immune Defic Syndr. 1990;3(10):954-8.PMID: 2204698 [PubMed - indexed for MEDLINE]Related articles

    15.

    Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

    Montefiori DC, Graham BS, Kliks S, Wright PF.

    J Clin Immunol. 1992 Nov;12(6):429-39.PMID: 1287035 [PubMed - indexed for MEDLINE]Related articles

    16.

    HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.

    Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M, et al.

    Clin Exp Immunol. 1994 Nov;98(2):178-84.PMID: 7955519 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

    Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, et al.

    J Infect Dis. 1992 Aug;166(2):244-52.PMID: 1353102 [PubMed - indexed for MEDLINE]Related articles

    18.

    A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

    Pialoux G, Excler JL, Rivière Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP, et al.

    AIDS Res Hum Retroviruses. 1995 Mar;11(3):373-81. Erratum in: AIDS Res Hum Retroviruses 1995 Jul;11(7):875. PMID: 7598771 [PubMed - indexed for MEDLINE]Related articles

    19.

    Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.

    Gorse GJ, Belshe RB, Newman FK, Frey SE.

    Vaccine. 1992;10(6):383-8.PMID: 1534641 [PubMed - indexed for MEDLINE]Related articles

    20.

    Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.

    Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD.

    Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2443-7.PMID: 8460155 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity